![Show Menu](styles/mobile-menu.png)
![Page Background](./../common/page-substrates/page0003.png)
Nanobiotechnology 2018
Page 21
Nano Research & Applications
ISSN: 2471-9838
E u r o S c i C o n C o n f e r e n c e o n
Nanotech & Nanobiotechnology
J u l y 1 2 - 1 3 , 2 0 1 8
P a r i s , F r a n c e
T
he address will be based on our strong belief that the future of science
in general and smart biomaterials and nanomedicines in particular is in
the interdisciplinary approach to hypotheses formulation and problem solving.
Nanoscience moved from copying/mimicking nature’s design to modify it and
designing bioactive materials. Our understanding of the relationship between
structure and properties reached levels needed for the design of totally new
materials different from those in nature. The latter approach has the highest
potential for scientific and application breakthroughs in the near future. The
nanomedicine field needs new ideas, so it can continue to enhance basic
scientific knowledge and translate the laboratory and animal model work into
humans. One new concept is called drug-free macromolecular therapeutics
(DFMT). The design of DFMT is based on molecular biorecognition, which is
at the center of all biological processes. Several therapeutic systems were
designed that do not contain a low molecular weight drug, but their therapeutic
efficacy is based on a combination of a macromolecule with a biorecognition
domain. Biological activity is a result of one or more biorecognition events. The
majority of studied systems are based on the crosslinking of receptors at the
cell surface of blood cancer cells. Other systems target E-selectin receptors in
the vasculature or focus on the biomineralization around cancer cells mediated
by receptor – ligand recognition.
Biography
Jindrich Kopecek received his PhD in Macromolecular
Chemistry from the Institute of Macromolecular Chemistry
(IMC) and DSc in Chemistry from the Czechoslovak Academy of
Sciences (CAS), Prague, Czech Republic. He has done his Post-
doctoral studies at the National Research Council of Canada.
He served as Laboratory Head at IMC CAS and is currently,
Distinguished Professor of Bioengineering and Distinguished
Professor of Pharmaceutical Chemistry at the University
of Utah. He serves on Editorial Boards of 14 international
scientific journals. He is an elected member of the US National
Academy of Engineering. His research interests are focused
on biorecognition of macromolecules, bioconjugate chemistry,
drug delivery systems, and self-assembled biomaterials.
Hydrogels from his laboratory have been in clinical use and
HPMA copolymer - anticancer drug conjugates in clinical trials.
His Hirsch index is 87; his publications have been cited 26,900
times.
Jindrich.kopecek@utah.eduChallenges and innovation in next generation nanoscience
Jinrich Kopecek, Jiyuan Yang and Lian Li
University of Utah, USA
Jinrich Kopecek et al., Nano Res Appl 2018, Volume 4
DOI: 10.21767/2471-9838-C2-011